JPWO2019224779A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019224779A5 JPWO2019224779A5 JP2020565864A JP2020565864A JPWO2019224779A5 JP WO2019224779 A5 JPWO2019224779 A5 JP WO2019224779A5 JP 2020565864 A JP2020565864 A JP 2020565864A JP 2020565864 A JP2020565864 A JP 2020565864A JP WO2019224779 A5 JPWO2019224779 A5 JP WO2019224779A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- lopinavir
- ritonavir
- hpv
- cervical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 27
- 206010008263 Cervical dysplasia Diseases 0.000 claims description 12
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims description 10
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 10
- 229960004525 lopinavir Drugs 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 10
- 229960000311 ritonavir Drugs 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 8
- 201000010881 cervical cancer Diseases 0.000 claims description 8
- 210000003679 cervix uteri Anatomy 0.000 claims description 8
- OFFWOVJBSQMVPI-RMLGOCCBSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O.N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 OFFWOVJBSQMVPI-RMLGOCCBSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 229940120922 lopinavir and ritonavir Drugs 0.000 claims description 7
- 230000002062 proliferating effect Effects 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 206010058314 Dysplasia Diseases 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 2
- 208000032124 Squamous Intraepithelial Lesions Diseases 0.000 claims 9
- 241000701806 Human papillomavirus Species 0.000 claims 5
- 208000009608 Papillomavirus Infections Diseases 0.000 claims 4
- 101150061050 CIN1 gene Proteins 0.000 claims 3
- 101150070189 CIN3 gene Proteins 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 101150005988 cin2 gene Proteins 0.000 claims 3
- 230000003232 mucoadhesive effect Effects 0.000 claims 3
- 208000007879 Atypical Squamous Cells of the Cervix Diseases 0.000 claims 2
- 235000021588 free fatty acids Nutrition 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 235000021313 oleic acid Nutrition 0.000 claims 1
- -1 ovule Substances 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1808564.7A GB201808564D0 (en) | 2018-05-24 | 2018-05-24 | Treatments |
| GB1808564.7 | 2018-05-24 | ||
| PCT/IB2019/054292 WO2019224779A1 (en) | 2018-05-24 | 2019-05-23 | Lopinavir and ritonavir for the treatment of cervix disorders |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021525266A JP2021525266A (ja) | 2021-09-24 |
| JPWO2019224779A5 true JPWO2019224779A5 (https=) | 2023-07-19 |
| JP2021525266A5 JP2021525266A5 (https=) | 2023-07-19 |
| JP7344911B2 JP7344911B2 (ja) | 2023-09-14 |
Family
ID=62812406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565864A Active JP7344911B2 (ja) | 2018-05-24 | 2019-05-23 | 頸部障害の処置のためのロピナビルおよびリトナビル |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11738024B2 (https=) |
| EP (1) | EP3801509A1 (https=) |
| JP (1) | JP7344911B2 (https=) |
| CN (1) | CN112203656B (https=) |
| AU (1) | AU2019274812B2 (https=) |
| BR (1) | BR112020023964A2 (https=) |
| CA (1) | CA3100425A1 (https=) |
| GB (1) | GB201808564D0 (https=) |
| MX (1) | MX2020012656A (https=) |
| SG (1) | SG11202010138WA (https=) |
| WO (1) | WO2019224779A1 (https=) |
| ZA (1) | ZA202006324B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201808563D0 (en) | 2018-05-24 | 2018-07-11 | Univ Manchester | Treatments |
| GB201808564D0 (en) | 2018-05-24 | 2018-07-11 | Douglas Pharmaceuticals Ltd | Treatments |
| GB201907305D0 (en) | 2019-05-23 | 2019-07-10 | Douglas Pharmaceuticals Ltd | Treatment of conditions |
| GB201917252D0 (en) * | 2019-11-27 | 2020-01-08 | Pharmaceutic compositions |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8822857D0 (en) | 1988-09-29 | 1988-11-02 | Patralan Ltd | Pharmaceutical formulations |
| DK2269591T3 (en) * | 2000-01-19 | 2018-07-16 | Abbvie Inc | IMPROVED PHARMACEUTICAL FORMULATIONS |
| CA2445967A1 (en) | 2001-05-01 | 2002-11-07 | Abbott Laboratories | Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents |
| US20030129208A1 (en) | 2002-01-07 | 2003-07-10 | Alberts David S. | Topical application of alpha-DFMO and anti-inflammatory drug for treatment of actinic keratoses |
| WO2004010937A2 (en) | 2002-07-26 | 2004-02-05 | Advanced Research & Technology Institute At Indiana University | Method of treating cancer |
| BR0302523A (pt) | 2003-07-23 | 2005-04-05 | Cristalia Prod Quimicos Farm | Composição farmacêutica estável para administração de inibidores da hiv protease e processo de obtenção de composição farmacêutica concentrada para a administração de inibidores da hiv protease |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| CA2582559A1 (en) | 2003-11-28 | 2005-06-16 | The University Of Manchester | Treatment of hpv infections and cancer |
| WO2008088806A1 (en) | 2007-01-16 | 2008-07-24 | Johns Hopkins University | Combinational paradigm combating hiv, hiv/hsv, or hiv/hpv infections in humans using small molecular weight compounds from plants |
| EP2280690A2 (en) | 2008-04-18 | 2011-02-09 | Nanobio Corporation | Methods for treating herpes virus infections |
| GB201006038D0 (en) | 2010-04-12 | 2010-05-26 | Unilever Plc | Improvements relating to antiviral compositions |
| KR20130139896A (ko) | 2010-09-08 | 2013-12-23 | 프로노바 바이오파마 너지 에이에스 | 유리산 형태의 epa 및 dha, 계면활성제, 및 스타틴을 포함하는 조성물 |
| GB201115635D0 (en) | 2011-09-09 | 2011-10-26 | Univ Liverpool | Compositions of lopinavir and ritonavir |
| PL3060211T3 (pl) | 2013-10-23 | 2020-07-27 | The University Of Manchester | Leczenie nowotworu i łagodnych chorób proliferacyjnych |
| WO2016123541A2 (en) | 2015-01-30 | 2016-08-04 | Tobira Therapeutics, Inc. | Cenicriviroc for the treatment of encephalitis infection |
| WO2019130341A1 (en) | 2017-12-26 | 2019-07-04 | Hetero Labs Limited | Capsule compositions comprising lopinavir and ritonavir |
| GB201808563D0 (en) | 2018-05-24 | 2018-07-11 | Univ Manchester | Treatments |
| GB201808564D0 (en) | 2018-05-24 | 2018-07-11 | Douglas Pharmaceuticals Ltd | Treatments |
| GB201808567D0 (en) | 2018-05-24 | 2018-07-11 | Douglas Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201808571D0 (en) | 2018-05-24 | 2018-07-11 | Douglas Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201907305D0 (en) | 2019-05-23 | 2019-07-10 | Douglas Pharmaceuticals Ltd | Treatment of conditions |
| GB201917252D0 (en) | 2019-11-27 | 2020-01-08 | Pharmaceutic compositions |
-
2018
- 2018-05-24 GB GBGB1808564.7A patent/GB201808564D0/en not_active Ceased
-
2019
- 2019-05-23 CN CN201980034993.5A patent/CN112203656B/zh active Active
- 2019-05-23 CA CA3100425A patent/CA3100425A1/en active Pending
- 2019-05-23 MX MX2020012656A patent/MX2020012656A/es unknown
- 2019-05-23 AU AU2019274812A patent/AU2019274812B2/en active Active
- 2019-05-23 US US17/055,048 patent/US11738024B2/en active Active
- 2019-05-23 BR BR112020023964-0A patent/BR112020023964A2/pt unknown
- 2019-05-23 WO PCT/IB2019/054292 patent/WO2019224779A1/en not_active Ceased
- 2019-05-23 EP EP19732473.4A patent/EP3801509A1/en active Pending
- 2019-05-23 JP JP2020565864A patent/JP7344911B2/ja active Active
- 2019-05-23 SG SG11202010138WA patent/SG11202010138WA/en unknown
-
2020
- 2020-10-12 ZA ZA2020/06324A patent/ZA202006324B/en unknown
-
2023
- 2023-06-30 US US18/216,937 patent/US20240148729A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rüdlinger et al. | Human papillomavirus-35-positive bowenoid papulosis of the anogenital area and concurrent human papillomavirus-35-positive verruca with bowenoid dysplasia of the periungual area | |
| US10543228B2 (en) | Pharmaceutical preparation containing selenite or selenite-containing compounds for treating cervical dysplasia or carcinomas | |
| CN112203656B (zh) | 用于治疗宫颈病症的洛匹那韦和利托那韦 | |
| Savoca et al. | CO 2 laser vaporization as primary therapy for human papillomavirus lesions: A prospective observational study | |
| Mudrikova et al. | HPV-related anogenital disease and HIV infection: not always ‘ordinary’condylomata acuminata | |
| CN101181636B (zh) | 一种防治人乳头瘤病毒感染的复方疫苗组合物、复方疫苗阴道喷雾剂及其用途 | |
| JPWO2019224779A5 (https=) | ||
| CN114053475A (zh) | 一种抗hpv医用妇科敷料 | |
| Stokes et al. | Human Papillomavirus Infections and Sequela in Women | |
| JP2017070310A (ja) | 上皮細胞におけるヒトパピローマウイルスゲノムの特異的なメチル化に関連する化合物および方法 | |
| Aşkın | Anogenital HPV | |
| CN112584828A (zh) | 人乳头瘤病毒高危感染的疗法 | |
| US20140341940A1 (en) | Immunomodulator for the treatment of cancerous tumors in the epithelial tissue lining surfaces inside or outside body organs | |
| JP2021536454A5 (https=) | ||
| Afshar et al. | Clinical and Public Health Considerations for HPV Infection in Men: A Narrative Review | |
| RU2747987C1 (ru) | Композиция для лечения латентной и субклинической папилломавирусной инфекции шейки матки и способ ее применения | |
| Bannerjee | Anogenital Warts | |
| EP4046646A1 (en) | Pharmaceutical composition for the treatment of hpv infections | |
| Kaminskiy et al. | 3.3. COMPARATIVE EFFECTIVENESS OF DIFFERENT PROTEFLAZID® FORMULATIONS IN THE TREATMENT OF MILD TO MODERATE CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) ASSOCIATED WITH GENITAL HPV INFECTION | |
| TW200800145A (en) | Hydrazone agents to treat cutaneous lesions | |
| CA3182703A1 (en) | Administration of homologous adenoviral vectors | |
| Sant’Ana et al. | Buschke-Lowenstein tumor in a patient with HIV and Psoriasis | |
| CN115581760A (zh) | 一种用于hpv病毒防治的凝胶及其制备方法 | |
| EA048333B1 (ru) | Терапия папилломавирусных инфекций человека высокого риска | |
| Conageski | A 25-Year-Old Woman with LSIL Desiring HPV Vaccination |